Addressing bone loss in the cancer survivor.
University of North Carolina, Greensboro School of Nursing Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Maureen E
ME
O'Rourke
Kathy
K
Ruble
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D005260:Female; D005485:Flutamide / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009369:Neoplasms / Q000628:therapy*; D010024:Osteoporosis / Q000139:chemically induced*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000451:nursing; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000451:nursing / Q000473:pathology / Q000601:surgery; D017741:Survivors
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D005485:Flutamide; D016729:Leuprolide